A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention
- PMID: 1762471
- DOI: 10.3109/14639239109067657
A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention
Abstract
In this paper a computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention is presented. Cost-effectiveness analysis makes it possible to compare the cost-effectiveness of different interventions in order to maximize the health effects for a given amount of resources. The computer simulation model was written in Turbo-Pascal to be used on an IBM-PC-compatible. The model was based on the 8-year logistic multivariate risk equations for CHD and stroke from the Framingham Heart Study, but the regression coefficients can easily be changed if local data exist. The main advantages with the model are that it is easy to use, transparent, and flexible. The model was mainly developed for scientific purposes, but should be useful also for educational purposes and clinical decision analysis. The modelling approach used should also be useful in many other medical areas.
Similar articles
-
Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.Clin Ther. 2009 Dec;31(12):2919-30; discussion 2916-8. doi: 10.1016/j.clinthera.2009.12.013. Clin Ther. 2009. PMID: 20110032
-
Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves.Med Decis Making. 2017 Oct;37(7):802-814. doi: 10.1177/0272989X17706081. Epub 2017 May 10. Med Decis Making. 2017. PMID: 28490271 Free PMC article.
-
A review of cost-effectiveness analyses.Med J Aust. 1990 Aug 6;153(S1):S20-3. doi: 10.5694/j.1326-5377.1990.tb136985.x. Med J Aust. 1990. PMID: 2116583
-
How cost-effective are new preventive strategies for cardiovascular disease?Am J Cardiol. 2003 May 22;91(10A):22G-27G. doi: 10.1016/s0002-9149(03)00229-7. Am J Cardiol. 2003. PMID: 12781905 Review.
-
Cost-effectiveness analysis of hypertension treatment--a review of methodological issues.Health Policy. 1991 Sep;19(1):55-77. doi: 10.1016/0168-8510(91)90074-8. Health Policy. 1991. PMID: 10117392 Review.
Cited by
-
Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model.Osteoporos Int. 2007 Jan;18(1):9-23. doi: 10.1007/s00198-006-0257-0. Epub 2006 Nov 9. Osteoporos Int. 2007. PMID: 17093892 Review.
-
Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.Pharmacoeconomics. 1994 Oct;6(4):370-400. doi: 10.2165/00019053-199406040-00004. Pharmacoeconomics. 1994. PMID: 10147474 Review.
-
Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs.Health Care Manag Sci. 2001 Dec;4(4):269-79. doi: 10.1023/a:1011838211092. Health Care Manag Sci. 2001. PMID: 11718459
-
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.Osteoporos Int. 2005 Jan;16(1):15-25. doi: 10.1007/s00198-004-1688-0. Epub 2004 Jul 24. Osteoporos Int. 2005. PMID: 15672210 Clinical Trial.
-
The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden.Osteoporos Int. 2008 Jun;19(6):819-27. doi: 10.1007/s00198-007-0511-0. Osteoporos Int. 2008. PMID: 18071650